Latest Conference Articles

Co-infection with malaria appears to give people who are infected with Ebola virus a better chance of recovering, Scripps Institute researchers found in West Africa.

No one was more shocked than local HIV specialists when an epidemic of HIV hit a small town in Indiana. Diane Janowicz, MD, a Bloomington, Indiana AIDS/HIV specialist gave ID Week attendees a detailed description of how she and other health officials and entities handled the case.

What do you do when you need to test drug therapies for Middle Eastern Respiratory Syndrome but the usual animal subjects do not get the disease? Easy, you just engineer a new kind of mouse.

Ian Crozier, MD, an infectious disease expert working treating Ebola patients in West Africa, had to admit himself to his own emergency treatment unit. His riveting account of his recovery included an episode in which virus lurking in one eye turned it from blue to green. Crozier got a standing ovation in his talk today at ID Week 2015 in San Diego, CA.

Cats and dogs can be vectors for an eye parasite, a multi-center team in the US Southwest reports. The parasite is called Onchocerca lupi. Six cases, believed to be the first in the US, are reported.

Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is effective at lowering disease activity long-term in patients with relapsing-remitting multiple sclerosis (RRMS), according to Eva Havrdova, MD, of Charles University of Prague. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

When it comes to treating and studying multiple sclerosis, the correlation between magnetic resonance imaging (MRI) lesions and actual disease activity has been widely disputed. A new analysis says that using MRI lesions as a proxy for disease activity is a sufficient approach when determining primary endpoints in clinical trials.

Doctors appear to be overprescribing fluoroquinolones for women with uncomplicated urinary tract infections.

Patients who are morbidly obese need a revised dosing protocol when getting vancomycin.

Canadian researchers found a "troubling trend" in an increase in dentists prescribing antibiotics to patients.

The results from an on-going phase 4 trial add to the growing evidence that teriflunomide is effective for relapsing-remitting multiple sclerosis, according to Patricia K. Coyle, MD, of Stony Brook University in New York.

Better understanding the relationship between inflammation and biomarkers could help improve treatments for those with multiple sclerosis.

Even when staph bacteria are not drug resistant, clinicians face prescribing drugs that could cause an adverse reaction including kidney injury. A Pittsburgh team looked at the comparative risk of nafcillin vs. oxacillin.

Healthcare providers need to remember the significance of the national issue of effectively combating antibiotic resistance.

Infection prevention is key in wanting to halt the rapid spread of antibiotic resistance.

Right now, what's really important is for hospital staff and healthcare providers to ensure their laboratories can detect antibiotic resistance accurately.

Scott Fridkin, MD, Senior Advisor for Antibiotic Resistance in Healthcare in the Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infections Diseases, CDC discussed how state programs can only flourish as healthcare professionals across the board implement existing public health guidelines into their practices.

Adding to research confirming the risk of administering piperacillin/tazobactam in combination with vancomycin, two research teams report that it does not matter whether the drugs are given in an extended infusion or standard infusion.

Vancomycin in combination with Beta-Lactams can cause acute kidney injury, and some combinations are worse than others, researchers warn.

Delayed-release dimethyl fumarate (DMF) proved to be safe and effective in two phase 3 studies, DEFINE and CONFIRM, for patients with relapsing-remitting multiple sclerosis (RRMS). Gavin Giovannoni, MBBCh, PhD, FRCP, FRCPath, of the Queen Mary University of London and colleagues took a more detailed look to verify the data.

Alemtuzumab is an effective strategy to prevent relapses and other disease activity associated with multiple sclerosis (MS), according to Heinz Wiendl, MD, a professor at the University of Münster. The research will be explained in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

Race and vitamin D levels may play a crucial role in the risk of multiple sclerosis (MS), according to Annette M. Langer-Gould, MD, PhD, of Kaiser Permanente in Pasadena, California. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

It may be the European Society of Cardiology's annual congress, but with abstract submissions from North America and Asia the recent event was further proof that the field is becoming more globalized while still holding to its Localized roots.

Obesity is a growing problem around the world and new research has shown that even small amounts of physical exercise can make a big difference in keeping people from gaining too much weight.

As the European Society of Cardiology wraps up another successful congress in London there remains a buzz about the work being done by doctors around the world to help patients with a variety of conditions.

As oral anticoagulants become more popular and a new generation of the drugs is introduced there are still some questions about the potential risks of taking the medication and whether they outweigh the benefits.

The European Society of Cardiology's annual conference in London highlighted some of the top work being done in the field over the past year.

PCSK9 inhibitors have been the focus of the cardiology community and with the approval of two medications in the past few months these drugs could soon make their way to a large number of patients needing help managing their cholesterol levels using more than just statins.

Congestive heart failure is a serious condition facing people around the world. Early trials of a gene therapy have showed promise to not only help these patients with the condition but also make their hearts healthier.

Just because researchers go into a study with a hypothesis they hope to prove, it does not mean the results will be what they were hoping for.